<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140802018649N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-07-08</date_registration>
      <primary_sponsor>Gorgan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of ultrafiltration profiling on hypotention during hemodialysis</public_title>
      <acronym></acronym>
      <scientific_title>Effect of liner, step-wise and functional ultrafiltration profiling on hypotension  during hemdialysis in patients with chronic renal failure</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/36346</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Prevention, Randomization description: 32 patients will be randomly blocked into four groups. Each block contains the letters A, B, C, and D, which patients will randomly place in these blocks. Then, the four groups will receive four different treatment protocols. Subjects in Group A will first receive Protocol 1, then 2, 3, and 4. Group B receives protocol 2, then 3, 4 and 1. Group C will also receive protocols 3, 4, 1 and 2, respectively. Group D will receive protocol 4, then 3, 2, and 1, Blinding description: The patient does not know that will be in which one of the four groups of treatment protocols.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Chronic kidney disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: group will receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below.At first, Protocol 1 include linear profiles of ultrafiltration, then protocol 2 including stepwise profiles, protocol 3 including functional profiles of ultrafiltration and protocol 4 include of fixed ultrafiltration,  each one for 2 weeks. Intervention 2: Intervention group2: group will  receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below.First, protocol 2 included a stepwise profile , then protocol 3: functional profile, protocol 4 include of  fixed ultrafiltration, and protocol 1 containing linear ultrafiltration, each one for 2 weeks. Intervention 3: Intervention group3: group will receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below. First, protocol 3 includes functional profiles, then protocol 4 including fixed ultrafiltration, next protocol 1 of linear ultrafiltration, and at the end protocol 2, including stapwise ultrafiltration profiles, each one for 2 weeks. Intervention 4: Intervention group: group will receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below.First, protocol 4 including fixed ultrafiltration, then protocol 1 of linear ultrafiltration, next protocol 2, including stapwise ultrafiltration and at the end protocol 3 includes functional profiles, each one for 2 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Khadijeh Yazdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shast Kola road, Falsafi Campus, booyeh Nursing and Midwifery school</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4934174515</zip>
        <telephone>+98 17 3245 6900</telephone>
        <email>yazdi@goums.ac.ir</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Saeid Amir Khanloo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sast Kola Road, Fasafi educational campus, Medical Faculty</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4934174515</zip>
        <telephone>+98 17 3245 1442</telephone>
        <email>amirkhanloo@goums.ac.ir</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>getting end stage renal failure
hemoglobin&gt;10
history of dialysis 3 months at least
Dialysis 3 times a week
Systolic blood pressure above 100 mm Hg before dialysis
Not use anti-hypertensive medication 4 hours before dialysis</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Classes 3 and 4  of Heart Failure
Hepatic Impairment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic kidney disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: group will receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below.At first, Protocol 1 include linear profiles of ultrafiltration, then protocol 2 including stepwise profiles, protocol 3 including functional profiles of ultrafiltration and protocol 4 include of fixed ultrafiltration,  each one for 2 weeks.</i_keyword>
      <i_keyword>Intervention group2: group will  receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below.First, protocol 2 included a stepwise profile , then protocol 3: functional profile, protocol 4 include of  fixed ultrafiltration, and protocol 1 containing linear ultrafiltration, each one for 2 weeks.</i_keyword>
      <i_keyword>Intervention group3: group will receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below. First, protocol 3 includes functional profiles, then protocol 4 including fixed ultrafiltration, next protocol 1 of linear ultrafiltration, and at the end protocol 2, including stapwise ultrafiltration profiles, each one for 2 weeks.</i_keyword>
      <i_keyword>Intervention group: group will receive ultrafiltration profiles in the form of protocols, each protocol will be implemented for a period of 2 weeks and overall 8 weeks  as below.First, protocol 4 including fixed ultrafiltration, then protocol 1 of linear ultrafiltration, next protocol 2, including stapwise ultrafiltration and at the end protocol 3 includes functional profiles, each one for 2 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood pressure. Timepoint: before hemodialysis, 1 hour, 2 hours, 3 hours and after hemodialysis. Method of measurement: sphygmomanometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gorgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-17</approval_date>
        <contact_name>Ethics Committee of Golestan University of Medical Sciences</contact_name>
        <contact_address>Booyeh Nursing and Midwifery Faculty, Falsafi educational Campus, Beginning of Shast Kola Road, Gorgan Gorgan Golestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
